A comprehensive genomic study by teams from the Wellcome Sanger Institute and University of Cambridge elucidates the distinct mutational signatures left by various chemotherapy agents on normal blood cells. This research analyzes blood cell genomes from patients treated with 21 different chemotherapy drugs and identifies drug-specific mutation patterns, providing critical insights that could inform personalized cancer treatment with reduced long-term toxicity.